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Introduction {#ehf212679-sec-0004}
============

Heart failure (HF) and ischaemic stroke share cardiovascular risk factors and have a high prevalence in the population. There is a twofold to threefold higher risk of ischaemic stroke and a higher risk of recurrent stroke in patients with chronic HF (CHF), compared with the general population.[1](#ehf212679-bib-0001){ref-type="ref"}, [2](#ehf212679-bib-0002){ref-type="ref"} There are several underlying pathophysiological mechanisms causing thromboembolism, that is, thrombus formation due to left ventricular hypokinesia, a hypercoagulable state due to increased aggregation of thrombocytes and reduced fibrinolysis. Furthermore, atrial fibrillation (AF) as a relevant risk factor for stroke is more often found in CHF patients than in the general population, which further increases the risk of ischaemic stroke.[3](#ehf212679-bib-0003){ref-type="ref"}

CHF patients more often suffer severe stroke and have a poor clinical outcome than do stroke patients without CHF.[1](#ehf212679-bib-0001){ref-type="ref"} In the acute phase of ischaemic stroke, cardiac function may be reduced, indicating that the heart and the brain are connected with several feedback mechanisms.[4](#ehf212679-bib-0004){ref-type="ref"}, [5](#ehf212679-bib-0005){ref-type="ref"}

The *Telemedical Interventional Monitoring in Heart Failure* (TIM‐HF) and *Telemedical Interventional Management in Heart Failure II studies* (TIM‐HF2) investigated the impact of remote non‐invasive telemedical care (NITC) on mortality and hospitalization in ambulatory CHF patients with New York Heart Association (NYHA) class II or III.[6](#ehf212679-bib-0006){ref-type="ref"}, [7](#ehf212679-bib-0007){ref-type="ref"} The TIM‐HF study demonstrated that NITC in ambulatory CHF patients was not associated with a reduction in all‐cause mortality if compared with usual care.[8](#ehf212679-bib-0008){ref-type="ref"} However, NITC was beneficial in the subgroup of patients with a *Patient Health Questionnaire* (PHQ‐9) score \< 10, a prior decompensation due to CHF within 12 months before randomization, and a left ventricular ejection fraction (LVEF) ≥ 25%, indicating that NITC may not appropriate for all CHF patients.[9](#ehf212679-bib-0009){ref-type="ref"} Considering these results, the main inclusion criteria and the amount of intervention of the TIM‐HF2 study were adapted---given in detail in the Methods section---and study results showed that NITC leads to fewer days lost owing to unplanned cardiovascular hospitalizations and all‐cause mortality.[10](#ehf212679-bib-0010){ref-type="ref"}

In this retrospective analysis of the pooled cohorts of the TIM‐HF studies, we focus on incidence, aetiology, and independent predictors for acute ischaemic stroke/transient ischaemic attack (TIA) in the follow‐up period of 12 months and the impact of NITC on the occurrence of acute ischaemic stroke/TIA. Furthermore, we highlight factors associated with known cerebrovascular disease at the time of randomization.

Methods {#ehf212679-sec-0005}
=======

Ethics and study design {#ehf212679-sec-0006}
-----------------------

Both trials, TIM‐HF and TIM‐HF2 (<http://clinicaltrails.gov> identifier NCT00543881 and NCT01878630), were approved by the ethics board of the Charité -- Universitätsmedizin Berlin (A1/052/07 and EA2/065/13). Detailed study design und results have been reported elsewhere.[6](#ehf212679-bib-0006){ref-type="ref"}, [7](#ehf212679-bib-0007){ref-type="ref"}, [8](#ehf212679-bib-0008){ref-type="ref"}, [9](#ehf212679-bib-0009){ref-type="ref"}, [10](#ehf212679-bib-0010){ref-type="ref"} In brief, the main common inclusion criteria in both studies were CHF NYHA II or III and ability to give informed consent. Randomization to intervention group NITC or usual care was 1:1 and stratified according to a central computerized randomization system.

NITC included daily measurements of blood pressure, body weight, electrocardiogram (ECG) (3 leads), SpO~2~, and self‐rated health status. Wireless data transfer was performed daily from the patients\' home directly to the Telemedical Center (TMC) at the Charité -- Universitätsmedizin Berlin, Germany.

The TMC served as a medical centre, not only collecting and monitoring data but also providing 24/7 physician‐led personalized patient support and management following a holistic approach (medication changes; initiation of ambulatory assessment by home physician; or hospitalization). An HF nurse visited the patients once at home within seven working days after randomization to perform three tasks: (i) train patients on how to use the four non‐invasive telemedical devices, (ii) perform a nursing assessment, and (iii) start an HF patient education programme, which was continued by monthly structured telephone interviews.

No recommendations were given to treating physicians of study patients, and no education programme was provided for the patients in the control group.

The inclusion criteria and endpoints of both studies were different to a certain extent: TIM‐HF included patients with LVEF of ≤ 35% and at least one hospitalization due to decompensated HF within 24 months prior to randomization. In patients with LVEF ≤ 25% (as documented two times within 6 months prior to randomization), no previous hospitalization due to CHF was required. Referring to the results of TIM‐HF study, the inclusion criteria of TIM‐HF2 were adapted as follows: LVEF ≤ 45% or \>45% with oral diuretics prescribed, hospitalization due to decompensated HF within 12 months prior to randomization, and depression score PHQ‐9 \< 10. In TIM‐HF, the primary outcome was all‐cause mortality during follow‐up (median 26 months). In TIM‐HF2, the primary endpoint was modified as follows: percentage of days lost due to unplanned cardiovascular hospitalizations or death from any cause (follow‐up time to a maximum of 393 days). In both studies, outpatient clinical visits were performed by a general practitioner or cardiologist at Months 3, 6, 9, and 12 (in TIM‐HF as well in Months 18 and 24) after randomization. The following data were recorded (TIM‐HF comparable with TIM‐HF 2): vital signs, CHF symptomatic status, NYHA class, changes in medication, information related to death from any cause, hospitalization, and emergency room admissions. Echocardiography was not required in these follow‐up visits. In both trials, a clinical endpoint committee, blinded to treatment allocation, classified all deaths and hospitalizations. For our investigation, prior cerebrovascular disease---including previous ischaemic and haemorrhagic stroke---was assessed at the time of enrolment. The presence of AF at the time of enrolment was assessed using the baseline 12‐lead ECG. In addition, daily ECG recordings of patients in the intervention group of both studies as well as the follow‐up visit ECGs after 12 months (in the intervention and the control group) were analysed in detail. Patients with no AF on the baseline study ECG but AF during daily recordings or ECG after 12 months and naive to anticoagulation were considered as patients with newly detected AF.

Statistical analyses {#ehf212679-sec-0007}
--------------------

Dichotomized and categorized characteristics were expressed as percentages. A two‐sided Pearson *χ* ^2^ test was performed for univariate analyses comparing patients with or without prior cerebrovascular disease on enrolment as well as with or without acute ischaemic stroke or TIA during follow‐up. Continuous data were presented as median and inter‐quartile range (IQR), and the Mann--Whitney *U* test was applied for univariate analysis. All tests were two‐tailed, and statistical significance was determined at an *α* level of 0.05. Multivariable logistic stepwise regression analyses were used to test for independent associations with cerebrovascular disease at enrolment or with ischaemic stroke or TIA in the follow‐up period. Adjustment was made for variables associated with *P* \< 0.05 in univariate comparisons. To prescribe the impact of serum levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) on stroke/TIA occurrence within 12 months and cerebrovascular disease at enrolment in more detail, we calculated three regression models: one with NT‐proBNP as a continuous variable and two further models with NT‐proBNP as an ordinal variable based on the tertiles and quartiles of the values. Statistical analyses were performed using SPSS software (version 24; SPSS, Chicago, Illinois) for Windows (Microsoft, Redmond, Washington).

Results {#ehf212679-sec-0008}
=======

Factors related to cerebrovascular disease at baseline {#ehf212679-sec-0009}
------------------------------------------------------

At randomization, 240 (10.7%) out of 2248 CHF patients had a medical history of cerebrovascular disease. This rate was similar in both studies (10.6% in TIM‐HF and 10.7% in TIM‐HF2). There was no information about the time of onset of the cerebrovascular disease before randomization. Baseline characteristics of study patients with or without prior cerebrovascular disease are given in *Table* [1](#ehf212679-tbl-0001){ref-type="table"}. According to the multivariate analysis, adjusting for all variables suggesting association of baseline recordings with a history of cerebrovascular disease at enrolment (*P* \< 0.05) (*Table* [1](#ehf212679-tbl-0001){ref-type="table"}), a history of hyperlipidaemia \[odds ratio (OR) 2.0, 95% confidence interval (CI) 1.4--2.7; *P* \< 0.001\], peripheral arterial occlusive disease (PAOD) \[OR 2.5, 95% CI 1.8--3.6; *P* \< 0.001\], body mass index (BMI) \[OR per point 0.9, 95% CI 0.92--0.98; *P =* 0.01\], and old age \[OR 1.03 per year 95% CI 1.0--1.1; *P* \< 0.001\] were independently associated with a history of cerebrovascular disease at baseline, while NT‐proBNP (as a continuous variable) was not \[OR per point 1.00, 95% CI 1.00--1.00; *P =* 0.81\]. With further sensitivity analysis using NT‐proBNP as a categorical variable for the multivariate analysis, whether patients are in the highest tertile (2203--34 869 pg/mL) (OR 1.4, 95% CI 1.0--2.2; *P =* 0.09) or patients are in the highest quartile (2941--34 869 pg/mL) of NT‐proBNP is independently associated with a cerebrovascular disease at randomization. In addition, we found no significant association of AF on ECG at randomization and cerebrovascular disease at baseline, while the time of onset of AF before randomization was unknown. There was an impact of prior cerebrovascular disease on all‐cause death (13.8% vs. 8.2%; *P =* 0.004) or cardiovascular death (8.8% vs. 4.2%; *P =* 0.001) during follow‐up.

###### 

Socio‐demographic factors and presence of cardiovascular risk factors in TIM‐HF and TIM‐HF2 patients with or without a history of cerebrovascular disease on enrolment

                                                                    History of cerebrovascular disease[a](#ehf212679-note-0003){ref-type="fn"}           *P*          
  ---------------------------------------------------------------- ---------------------------------------------------------------------------- --------------------- ---------
  Socio‐demographic factors                                                                                                                                           
  Sex, female, % (*n*)                                                                              27.0 (539)                                        24.2 (58)       0.30
  Age, years, median \[IQR\]                                                                      71 \[62--77\]                                     74 \[67--78\]     \<0.001
  Body mass index, kg/m^2^, median \[IQR\]                                                     28.6 \[25.0--32.0\]                               26.7 \[23.8--30.6\]  \<0.001
  Randomized to telemedicine, % (*n*)                                                               49.7 (993)                                       50.8 (122)       0.74
  Cardiovascular risk factors                                                                                                                                         
  Diabetes mellitus, % (*n*)                                                                        42.3 (863)                                       47.7 (114)       0.184
  Hypertension, % (*n*)                                                                            76.2 (1516)                                       80.3 (192)       0.15
  Hyperlipidaemia, % (*n*)                                                                         60.3 (1153)                                       76.8 (179)       \<0.001
  Current smoking, % (*n*)                                                                          10.8 (211)                                        6.0 (14)        0.02
  Peripheral arterial occlusive disease, % (*n*)                                                    9.8 (189)                                         24.9 (58)       \<0.001
  Medical history regarding to cardiologic diagnosis or findings                                                                                                      
  Coronary heart disease, % (*n*)                                                                  59.7 (1170)                                       73.8 (172)       \<0.001
  Dilated cardiomyopathy, (*n*)                                                                     40.8 (807)                                        31.2 (74)       0.004
  Left ventricular ejection fraction, median \[IQR\]                                              35 \[25--45\]                                     30 \[25--50\]     0.36
  NT‐proBNP, pg/mL, median \[IQR\]                                                              1340 \[579--2863\]                               1914 \[988--3404\]   \<0.001
  Mean arterial pressure, mmHg, median \[IQR\]                                                 90.7 \[83.3--98.3\]                               89.3 \[80.0--96.7\]  0.90
  Atrial fibrillation on ECG at randomization, % (*n*)                                              31.5 (626)                                        33.8 (81)       0.47

MWU, Mann‐Whitney‐U‐test; NT‐proBNP, N‐terminal pro brain natriuretic peptide.

In 10 out of 2248 patients, there was no information about a history of cerebrovascular disease at enrolment.

Ischaemic stroke or transient ischaemic attack during follow‐up {#ehf212679-sec-0010}
---------------------------------------------------------------

Within 12 months after randomization, 33 ischaemic stroke‐related hospitalizations were reported. As one patient suffered from two strokes, 32 (1.4%) study patients were included into this analysis. Of these, 26 (81%) patients had an ischaemic stroke and six (19%) patients had a TIA. This corresponds to an ischaemic stroke rate of 1.2 per 100 patient‐years, a TIA rate of 0.3 per 100 patient‐years, and a total stroke/TIA rate of 1.5 per 100 patient‐years of follow‐up. Two additional patients were hospitalized owing to intracerebral haemorrhage during the follow‐up period.

Baseline characteristics of study patients with or without ischaemic stroke/TIA during follow‐up were given in *Table* [2](#ehf212679-tbl-0002){ref-type="table"}. On admission, the median *National Institutes of Health Stroke Scale* score was 3 (IQR 2--6) points, indicating a moderate stroke‐related deficit in the majority of patients. Based on medical records, the aetiology of ischaemic stroke/TIA was classified to be 'cardio‐embolic' in 22 (69%) patients, microangiopathic in two (6%) patients, macroangiopathic in six (19%) patients, and cryptogenic in one (3%) patient according to *Trial of ORG 10172 in Acute Stroke Treatment* criteria.[11](#ehf212679-bib-0011){ref-type="ref"} The medical records of one patient with stroke/TIA in the follow‐up period were incomplete. AF was present in 19 (59%) ischaemic stroke/TIA patients (including those with a history of paroxysmal AF); in 12 of these 19 patients, anticoagulation was established before the onset of acute stroke/TIA. Eighteen (56%) patients underwent echocardiography (14 transthoracic echo and four transthoracic and transesophageal echo) in the acute phase of ischaemic stroke/TIA (*Table* [3](#ehf212679-tbl-0003){ref-type="table"}).

###### 

Univariate comparison of baseline variables of chronic heart failure patients with or without ischaemic stroke or transient ischaemic attack during study follow‐up

                                                                 Ischaemic stroke or TIA           *P*          
  ------------------------------------------------------------- ------------------------- --------------------- ------
  Socio‐demographic factors                                                                                     
  Sex, female, % (*n*)                                                  37.5 (12)              26.6 (589)       0.69
  Age, years, median \[IQR\]                                       73.0 \[64.5--78.0\]     71.0 \[63.0--77.0\]  0.29
  Body mass index, kg/m^2^, median \[IQR\]                         26.6 \[23.4--33.8\]     28.4 \[24.9--32.7\]  0.27
  Randomized to telemedicine, % (*n*)                                   50.0 (16)              49.8 (1103)      0.98
  Cardiovascular risk factors                                                                                   
  Diabetes mellitus, % (*n*)                                            50.0 (16)              43.7 (967)       0.47
  Hypertension, % (*n*)                                                 75.0 (24)              76.8 (1694)      0.82
  Hyperlipidaemia, % (*n*)                                              58.6 (17)              62.3 (1323)      0.69
  Current smoking, % (*n*)                                               9.4 (3)               10.3 (222)       0.87
  Peripheral arterial occlusive disease, % (*n*)                        25.8 (8)               11.3 (241)       0.01
  History of cerebrovascular disease, % (*n*)                           18.8 (6)               10.6 (234)       0.14
  Medical history regarding cardiologic diagnosis or findings                                                   
  Coronary heart disease, % (*n*)                                       70.0 (21)              61.1 (1327)      0.32
  Dilated cardiomyopathy, % (*n*)                                       29.0 (9)               40.0 (878)       0.21
  Left ventricular ejection fraction, median \[IQR\]                  35 \[25--50\]           34 \[25--45\]     0.56
  NT‐proBNP^a^ pg/mL, median \[IQR\]                               2217 \[1263--3804\]     1385 \[596--2920\]   0.02
  Mean arterial pressure, mmHg, median \[IQR\]                    92.2 \[78.6--100.0\]     90.0 \[83.3--98.3\]  0.83
  Atrial fibrillation on ECG at randomization, % (*n*)                  34.4 (11)              31.7 (700)       0.75
  Current medication                                                                                            
  Acetylsalicylic acid, % (*n*)                                         43.8 (14)              39.8 (883)       0.65
  Other antithrombotic medication, % (*n*)                              28.1 (9)               15.0 (332)       0.05
  Anticoagulation, % (*n*)                                              53.1 (17)              56.9 (1260)      0.67

NT‐proBNP, N‐terminal pro brain natriuretic peptide.

###### 

Data of in‐hospital assessment in 33 TIM‐HF or TIM‐HF2 patients with acute ischaemic stroke or transient ischaemic attack during the follow‐up period.

   No.   Diagnosis  NIHSS on admission   Aetiology of ischaemic stroke/TIA   AF    Stroke prevention on admission   Stroke prevention at discharge    LVEF (%) at randomization   LVEF (%) at the time of stroke  Intracardiac thrombi
  ----- ----------- -------------------- ----------------------------------- ----- -------------------------------- -------------------------------- --------------------------- -------------------------------- ----------------------
    1     Stroke    10                   Cardio‐embolic                      Yes   Unknown                          LMH 1 × 60 mg (VKA r)                        27                             20                No
    2     Stroke    2                    Cardio‐embolic                      No    VKA                              VKA                                          35                             30                No
    3       TIA     1                    Cardio‐embolic                      Yes   VKA                              VKA                                          20                          Unknown              Unknown
    4     Stroke    3                    Cardio‐embolic                      Yes   VKA                              VKA                                          20                             22                Yes
    5     Stroke    2                    Cardio‐embolic                      Yes   unknown                          VKA                                          25                          Unknown              Unknown
    6     Stroke    3                    Cardio‐embolic                      No    ASA                              CLP                                          25                             20                no
    7     Stroke    4                    Microangiopathy                     No    APA                              APA                                          29                          Unknown              Unknown
    8     Stroke    5                    Cardio‐embolic                      No    VKA                              VKA                                          34                           normal              No
    9     Stroke    14                   Cardio‐embolic                      Yes   none                             CLP + ASS (VKA r)                            20                          Unknown              Unknown
   10     Stroke    6                    Cardio‐embolic                      No    ASA                              ASA + APA                                    15                             25                No
   11     Stroke    6                    Macroangiopathy                     No    ASA                              ASA                                          35                          Unknown              Unknown
   12     Stroke    5                    Cardio‐embolic                      Yes   ASS                              Eliquis                                      42                             45                No
   13     Stroke    6                    Cardio‐embolic                      Yes   VKA                              ASS + VKA                                    35                          Unknown              Unknown
   14       ZAV     1                    Cardio‐embolic                      Yes   VKA                              VKA                                          55                          Unknown              Unknown
   15     Stroke    18                   Cardio‐embolic                      Yes   ASS                              ASS                                          70                             61                No
   16     Stroke    4                    Cardio‐embolic                      Yes   VKA                              Eliquis                                      35                          Unknown              Unknown
   17     Stroke    3                    Cardio‐embolic                      Yes   VKA                              Eliquis                                      55                             60                No
   18       TIA     1                    Microangiopathy                     No    ASS                              ASS                                          25                             35                No
   19     Stroke    2                    Cardio‐embolic                      Yes   Eliquis                          Eliquis                                      50                          Unknown              Unknown
   20       TIA     2                    Cardio‐embolic                      Yes   VKA                              Xarelto                                      63                             71                no
   21     Stroke    6                    Cardio‐embolic                      Yes   Heparin, AC                      n.a. exitus letalis                          55                          Unknown              Unknown
   22     Stroke    5                    Macroangiopathy                     No    ASA                              ASA                                          40                             40                No
   23     Stroke    8                    Cardio‐embolic                      Yes   none                             Eliquis                                      45                      Slightly reduced         No
   24     Stroke    4                    Cardio‐embolic (endocarditis)       Yes   VKA                              VKA                                          50                           Normal              No
   25     Stroke    6                    Cardio‐embolic                      Yes   Heparin, TP                      Heparin, TP                                  44                             36                No
   26     Stroke    2                    Cryptogenic                         Yes   APA                              APA                                          35                          Unknown              Unknown
   27     Stroke    3                    Macroangiopathy                     No    ASA                              ASA+APA                                      41                             37                No
   28       TIA     2                    Macroangiopathy                     No    APA                              APA                                          20                             20                No
   29     Stroke    3                    Cardio‐embolic                      Yes   VKA                              VKA                                          60                           Normal              No
   30       TIA     0                    Macroangiopathy                     No    VKA                              VKA                                          40                          Unknown              Unknown
   31       TIA     0                    Macroangiopathy                     No    ASA                              ASA                                          26                          Unknown              Unknown
   32     Stroke    Unknown              Unknown                             No    Unknown                          ASA                                          52                          Unknown              Unknown

AF, atrial fibrillation; APA, anti‐platelet agent other than ASA; ASA, acetylsalicylic acid; LMH, low molecular heparin; LVEF, left ventricular ejection fraction, patient died during intra‐hospital stay; n.a., not applicable; NIHSS, National Institutes of Health Stroke Scale; r, recommended; TIA = transient ischaemic attack; VKA, Vit K antagonist.

According to the univariate analysis, age \[median 73 years, IQR (65--78) vs. 71, IQR (63--77); *P =* 0.29\], AF (34.4% vs. 31.7%; *P =* 0.75), or prior cerebrovascular disease (18.8% vs. 10.6%; *P =* 0.14) showed no association with ischaemic stroke/TIA during the follow‐up period. An association with ischaemic stroke/TIA during the follow‐up period was given for PAOD and serum levels of NT‐proBNP according to the univariate analysis. According to the multivariate analysis using backward selection, patients in the highest tertile (2203--34 869 pg/mL) (OR 3.4, 95% CI 1.1--8.3; *P =* 0.03) of NT‐proBNP as well as patients with a history of PAOD (OR 2.7, 95% CI 1.2--6.2; *P =* 0.02) remained independently associated with ischaemic stroke/TIA during follow‐up, while NT‐proBNP as a continuous variable (OR per point 1.00, 95% CI 1.00‐1.00; *P =* 0.79) was not. With the use of quartiles of serum levels of NT‐proBNP on enrolment, the highest quartile (2941--34 869 pg/mL) was also independently associated with ischaemic stroke/TIA during follow‐up (OR 3.7, 95% CI 1.04--13.3; *P =* 0.04). Patients with ischaemic stroke/TIA during follow‐up died significantly more often within 1 year after randomization than did patients without ischaemic stroke/TIA during follow‐up (21.9% vs. 8.5%; *P =* 0.008). There was no statistically difference between both groups regarding cardiovascular death (6.2% vs. 4.5% *P =* 0.66).

We compared additionally baseline data of all patients randomized in both studies (*Table* [S1](#ehf212679-supitem-0001){ref-type="supplementary-material"}, *n* = 2248) and of those with stroke/TIA within the analysed follow‐up time period of 12 months (*Table* [S2](#ehf212679-supitem-0001){ref-type="supplementary-material"}, *n* = 32) with regard to their randomization. However, there was no significant difference here.

Non‐invasive telemedical care and ischaemic stroke/transient ischaemic attack {#ehf212679-sec-0011}
-----------------------------------------------------------------------------

The stroke/TIA rate in the intervention group (1.4%) compared with the control group (1.4%; *P =* 0.98) was similar. AF was detected newly in 176 (7.8%) patients after randomization within the pooled cohort of the TIM‐HF and TIM‐HF2 studies. The rate of newly detected AF in the intervention group (*n* = 158) was significantly higher than in the control group (*n* = 18) (14.1% vs. 1.6%; *P* \< 0.001). The summarized rate of established oral anticoagulation 12 months after randomization (43.3% vs. 38.8%; *P =* 0.03) was significantly higher in patients randomized to the intervention group than in the control group of TIM‐HF or TIM‐HF2.

Compared with study patients without stroke/TIA within 12 months after randomization, the summarized rate of newly detected AF (12.5% vs. 7.8%; *P =* 0.32) or the summarized rate of established oral anticoagulation at 12 months after randomization (40.6% vs. 41.1%; *P =* 0.96) was not different in study patients with stroke/TIA.

Discussion {#ehf212679-sec-0012}
==========

This retrospective analysis of the prospective randomized TIM‐HF and TIM‐HF2 studies revealed a rather low annual rate of ischaemic stroke/TIA (1.5 per 100 person‐years) in CHF patients with NYHA II or III. Elevated NT‐proBNP levels and a history of PAOD at baseline were related to higher risk of stroke/TIA during follow‐up. The aetiology of ischaemic stroke/TIA was predominantly assumed to be cardio‐embolic, but diagnostic workup of \~44% of all patients did not include diagnostic echocardiography during the in‐hospital stay after acute stroke/TIA.

Both studies, TIM‐HF and TIM‐HF2, were designed to investigate the impact of NITC on mortality and hospitalization in ambulatory CHF patients with NYHA class II or III. Taking into consideration that these studies were not designed to investigate the impact of NITC on ischaemic stroke/TIA, this analysis showed no benefit of NITC concerning prevention of stroke or TIA in CHF patients. The daily ECG analysis within the intervention group leads to a significantly higher rate of newly detected AF in comparison with that of the control group. Interestingly, neither AF on baseline ECG nor newly detected AF after randomization had an impact on stroke rate during follow‐up in our analysis.

So far, the reported annual stroke rates in CHF patients range from 1.1 to 4.6 per 100 person‐years.[4](#ehf212679-bib-0004){ref-type="ref"}, [12](#ehf212679-bib-0012){ref-type="ref"}, [13](#ehf212679-bib-0013){ref-type="ref"} As CHF severity and aetiology of HF may impact the incidence rate of ischaemic stroke/TIA[1](#ehf212679-bib-0001){ref-type="ref"}, [14](#ehf212679-bib-0014){ref-type="ref"} the exclusion of CHF patients with NYHA‐IV and physical and mental disabilities in both studies according to inclusion criteria may have caused the comparably low incidence of ischaemic stroke/TIA. In TIM‐HF and TIM‐HF2, the main documented CHF aetiology was ischaemic cardiomyopathy, but we detected no impact of CHF aetiology on ischaemic stroke/TIA rate during the follow‐up. AF detected on a 12‐lead ECG on enrolment was known in 32% of all included patients. Published data reported even higher rates of AF in HF patients.[3](#ehf212679-bib-0003){ref-type="ref"} In addition, known risk factors for ischaemic stroke like a history of arterial hypertension, old age, prior stroke, or diabetes showed no impact in the present analysis including CHF patients.[15](#ehf212679-bib-0015){ref-type="ref"} According to the multivariate analysis, the highest tertile or the highest quartile of serum NT‐proBNP on enrolment was an independent predictor for ischaemic stroke/TIA during follow‐up, which is in line with reported results of a pooled analysis.[14](#ehf212679-bib-0014){ref-type="ref"} Also in accordance with other publications, CHF patients with ischaemic stroke/TIA during follow‐up more often died than do CHF patients without ischaemic stroke/TIA.[1](#ehf212679-bib-0001){ref-type="ref"}, [4](#ehf212679-bib-0004){ref-type="ref"}

Detailed information regarding in‐hospital diagnostic workup after acute ischaemic stroke/TIA is given in *Table* [3](#ehf212679-tbl-0003){ref-type="table"}. Despite---or probably even of---known CHF, echocardiography was not performed in 44% of acute stroke patients. The presence of AF and the subsequent need of oral anticoagulation almost independent of echocardiographic findings may be an explanation, as AF was present in eight out of 13 stroke/TIA patients without echocardiography. In our mind, a transesophageal echocardiography is justified to rule out left atrial or left ventricular thrombi or valve vegetations.[5](#ehf212679-bib-0005){ref-type="ref"} Evidence of cardiac thrombus would result in an anticoagulation therapy even in patients without AF. Because of the observed diagnostic shortcomings, we are limited to describe the impact of acute ischaemic stroke on cardiac function in detail (e.g. stroke‐induced HF).[4](#ehf212679-bib-0004){ref-type="ref"} Not surprisingly, stroke aetiology was most often assumed to be cardio‐embolic in CHF patients.[9](#ehf212679-bib-0009){ref-type="ref"}

The pooled analysis of TIM‐HF cohorts revealed that a history of cerebrovascular disease---including previous ischaemic and/or haemorrhagic stroke---on enrolment was related to old age, a history of hyperlipidaemia, history of PAOD, or presence of lower BMI. Body weight loss is a common observed condition after acute and chronic stroke. A stroke‐related metabolic imbalance and ongoing systematic inflammation in chronic stroke as some explanatory approaches are under discussion.[16](#ehf212679-bib-0016){ref-type="ref"} All other variables associated with the presence of cerebrovascular disease at baseline are well‐known cardiovascular risk factors.

Besides the reported strengths, the major limitation of the reported findings is the retrospective design of this analysis. Although a prior stroke was not defined as exclusion criterion, we have to consider that patients might have been excluded from the study owing to stroke‐related disability. Furthermore, there was no information available concerning the individual prescreening before enrolment. In addition, the comparably low stroke rate during follow‐up may have influenced our findings. There was no continuous ECG or blood pressure monitoring in the intervention arm of both studies; therefore, some parameters that may be relevant regarding occurrence of a stroke/TIA like AF burden, heart rate variability, or the presence of nocturnal dip of blood pressure are missing in this analysis. Patients with higher atherosclerotic burden (older age and history of PAOD) had a higher incidence of cerebrovascular disease at baseline and/or stroke/TIA in 12 months after randomization in this analysis. Because there are no data regarding aortic calcification, supra‐aortic vessel status, or aortic pressure control, we are not able to analyse this in detail.

Conclusions {#ehf212679-sec-0013}
===========

The overall stroke rate during the follow‐up of the TIM‐HF studies was rather low. NITC to reduce mortality and hospitalization of CHF patients had no impact on the stroke/TIA rate. CHF patients with higher levels of NT‐proBNP and a history of PAOD at baseline were under a higher risk to suffer ischaemic stroke/TIA during follow‐up. Whether a biomarker‐guided (e.g. NT‐proBNP) management may influence the stroke/TIA rate in CHF patients had to be investigated in a randomized prospective trial. In a substantial number of CHF patients, echocardiography was not included in the diagnostic workup after acute ischaemic stroke/TIA. From our point of view, a transesophageal echocardiography is indicated in those patients to rule out cardiac thrombi or valve vegetation.
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